Navigation Links
Cleveland Clinic researchers investigating potential drug for treatment of Alzheimer's disease
Date:8/31/2012

Friday, Aug. 31, 2012, Cleveland: A compound developed to treat neuropathic pain has shown potential as an innovative treatment for Alzheimer's disease, according to a study by researchers at Cleveland Clinic's Lerner Research Institute and Anesthesiology Institute.

"Cleveland Clinic dedicated two years of research into the examination of this compound and our findings show it could represent a novel therapeutic target in the treatment of Alzheimer's disease," said Mohamed Naguib, M.D., Professor of Anesthesiology, Cleveland Clinic Lerner College of Medicine. "Development of this compound as a potential drug for Alzheimer's would take many more years, but this is a promising finding worthy of further investigation."

In a study published online in the Neurobiology of Aging, the compound MDA7 induced beneficial immune responses that limited the development of Alzheimer's disease. Treatment with the compound restored cognition, memory and synaptic plasticity a key neurological foundation of learning and memory in an animal model.

Neuroinflammation is an important mechanism involved in the progression of Alzheimer's disease. The MDA7 compound has anti-inflammatory properties that act on the CB2 receptor one of the two cannabinoid receptors in the body but without the negative side effects normally seen with cannabinoid compounds.

Alzheimer's disease is an irreversible, fatal brain disease that slowly destroys memory and thinking skills. About 5 million people in the United States have Alzheimer's disease. With the aging of the population, and without successful treatment, there will be 16 million Americans and 106 million people worldwide with Alzheimer's by 2050, according to the 2011 Alzheimer's Disease Facts and Figures report from the Alzheimer's Association.


'/>"/>

Contact: Joe Milicia
milicij2@ccf.org
216-636-5873
Cleveland Clinic
Source:Eurekalert

Page: 1

Related medicine news :

1. Cleveland Clinic selected to participate in National MDS Clinical Research Consortium
2. Cleveland Clinic researchers discover molecule that may prevent atherosclerosis
3. Cleveland Clinic Florida receives approval for transplant programs at Weston Facilities
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. First targeted nanomedicine to enter human clinical studies
6. Clinical insight improves treatment with new lung cancer drug
7. Clinical news alert from the American Academy of Orthopaedic Surgeons
8. Mayo Clinic launches whole genome breast cancer study
9. Mayo Clinic offers newly approved treatment for acid reflux disease
10. NYU Langone experts present research, clinical advances at neurosurgeons meeting
11. Mayo Clinic breast cancer study finds new type of mutation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... ... production of its newest mobility device, the StandUp Walker. Made entirely in the ... in the last 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus ... the continuation of the ‘Pay It Forward’ program into 2016. BioPlus partners with ... our specialty pharmacy. , “Since our Pay It Forward program began, we ...
(Date:2/9/2016)... ... 09, 2016 , ... The Bon-Ton Stores, Inc. (NASDAQ: BONT), ... announced it has raised $176,000 to benefit the Breast Cancer Research Foundation, Froedtert ... the University of Iowa, The Lynn Sage Cancer Research Foundation, and Masonic Cancer ...
(Date:2/9/2016)... ... February 09, 2016 , ... IsoComforter, Inc., one of ... the newly designed, innovative shoulder wrap. The newly designed shoulder wrap has ... injured arm and shoulder to promote faster healing. It is highly recommended for ...
(Date:2/9/2016)... ... , ... i2i Systems, an early innovator and developer of population health management ... KLAS report, Population Health Management 2015: How Far Can Your Vendor Take You? ... (PHM). The latest KLAS Report, leveraging over 200 user interviews, shines a light ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 2016 The new report "Global Blood Monitoring & Cardiac Monitoring Devices ... Consulting group reveals that global market for blood monitoring & cardiac ... expected to grow to US$ 24,830.1 million by 2019 at a ... America , Europe , Asia-Pacific ... and Africa . The three major ...
(Date:2/9/2016)... , Feb. 9, 2016  Johnson & Johnson ... Capital Markets Global Healthcare Conference on Tuesday, Feb. 23, ... Dominic Caruso , Vice President, Finance & Chief ... Consumer will represent the Company in a session scheduled ... . --> www.investor.jnj.com . --> ...
(Date:2/9/2016)... , Feb. 9, 2016  Bluestar Silicones will ... product line for long-term implant applications and announce ... Design & Manufacturing (MD&M) West Conference (Booth #1759), ... --> --> Available ... Biomedical LSRs offer outstanding physical properties enabling our ...
Breaking Medicine Technology: